Scientists test custom drug matching for tough blood cancers
NCT ID NCT03389347
Summary
This pilot study is testing whether using genetic data and lab tests on a patient's cancer cells can help doctors choose more effective drugs for multiple myeloma or plasma cell leukemia that has returned or stopped responding to standard treatments. Researchers analyze bone marrow and blood samples to see which drugs kill a patient's specific cancer cells best in the lab. The goal is to see if this personalized approach is practical and can lead to better treatment choices for these difficult-to-treat blood cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.